AfterRaise/Companies/Estuary Biotherapeutics

Estuary Biotherapeutics

Estuary Biotherapeutics is a biotechnology company developing genetic medicines for patients with serious kidney diseases. From its funding announcement.

$93M Series ARaised yesterdayNewton, USABiotech & PharmaUSA
Visit website →

In their own words

What Estuary Biotherapeutics says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "biotechnology company developing genetic medicines for patients with serious kidney diseases". Source

Product

Public signal Read from the company's own description of what the funding supports.

Why now

Where Estuary Biotherapeutics is today

Estuary Biotherapeutics announced a Series A round of $93M on 19 October 2026, led by RA Capital Management.

Latest round
Series A
Amount
$93M
Announced
19 October 2026
Headquarters
Newton, USA
Sector
Biotech & Pharma
Investors
Also participating
Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, National Kidney Foundation Innovation Fund, 4BIO Capital, GV, family office connected to an individual living with autosomal dominant polycystic kidney disease (ADPKD
Relevant leadership
co-founder and CEO Wayne Sackett

Momentum AfterRaise intelligence

AfterRaise Score

74
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
19/25
round size relative to the market
Funding stage
15/20
Series A
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 19 October 2026
    $93M Series A
    Led by RA Capital Management.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Product launches and new tiers
  • Product leadership hiring
  • Accelerated hiring across functions
  • Repeatable go-to-market build

Opportunities this could create

  • Licensing and BD partnerships
  • Product leadership
  • Design partners
  • Specialist engineering
  • Clinical operations

Based on the Biotech & Pharma sector, a Series A round and the priorities the company itself set out. Not a statement of fact.

Medium momentum2 connected signals
  • 19 October 2026$93M Series A announced
  • 19 October 2026Stated priority: product

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Estuary Biotherapeutics is open to

Not yet specified

Estuary Biotherapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Estuary Biotherapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Estuary Biotherapeutics?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector